Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics After Fosamprenavir (FPV) and Raltegravir (RTG) Are Each Administered Alone Versus in Combination With or Without Ritonavir (RTV) Boosting in Healthy Adult Subjects

NCT00614991 is registered in ClinicalTrials.gov with Garden State Infectious Disease Associates, PA as lead sponsor.

NCT NCT00614991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00614991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics After Fosamprenavir (FPV) and Raltegravir (RTG) Are Each Administered Alone Versus in Combination With or Without Ritonavir (RTV) Boosting in Healthy Adult Subjects
Lead sponsor
Garden State Infectious Disease Associates, PA
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2008
Enrollment
44 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy